UsingGeospatialMapping and EpidemiologicMethods to Identify and SupportPersonsWhoInjectDrugs (PWID) at Risk for HIV in Alabama
Project Number3P30AI027767-35S5
Former Number5P30AI027767-34
Contact PI/Project LeaderHEFFRON, RENEE A.
Awardee OrganizationUNIVERSITY OF ALABAMA AT BIRMINGHAM
Description
Abstract Text
SUMMARY
Due to the large, rural burden of HIV in the state, Alabama (AL) is one of seven priority states for the Ending the
HIV Epidemic (EHE) initiative. Alabamians struggle with late HIV diagnosis and suboptimal linkage and retention
in HIV care, at least in part due to poverty, rurality, and lack of public health infrastructure and Medicaid
expansion. Further, historic events have impacted HIV efforts in AL in myriad ways, halting progress towards
EHE goals: the pandemic and the Drug Crisis. At UAB Hospital, one hundred of personswhoinjectdrugs (PWID)
are hospitalized with serious complications from drug use annually. Over 25% of them are from rural counties
where the absence of low barrier medical, harm reduction, and addiction services enables high riskinjection
practices and infections, like hepatitis C and HIV. Unfortunately, the hospital is a missed opportunity for HIV
prevention: we found that hospitalized PWID are unaware of their HIVrisk and providers are unlikely to offer
PrEP to PWID. At the same time, few PWID in AL reside in communities that offer integrated HIV, harm reduction,
and addiction services. Thus, PWID with life-threatening complications of drug use return to communities who
are not equipped to care for them. While it is not feasible to rapidly scale up integrated care across Alabama, a
combination of geospatialmapping and epidemiologic surveillance can allow us to identify and prioritize counties
at greatest risk for an HIV outbreak among PWID. The objective of this application is to 1) leverage hospital and
community-level data to identify AL counties at greatest risk for an HIV outbreak among PWID and 2) engage
community partners to identify needs and opportunities to build community capacity. The overall goal of this
proposal is to inform implementation strategies to integrate person-centered HIV, harm reduction, and addiction
services for PWID in AL. To achieve our overall goal, we propose the following specific aims:
AIM 1A. Usinggeospatialmapping and statewide HIV and opioid overdose surveillance data, we will identify AL
counties with the greatest risk of an HIV outbreak during the contemporary drug crisis (fentanyl and
methamphetamines).
AIM 1B. Upon identifying counties with the greatest risk, we will work in partnership with our existing Community
Advisory Board (CAB) to develop an engaged community of partners in counties at greatest risk, including health
officials, AIDS Service Organizations, nonprofits, and addiction treatment centers.
AIM 2. We will collaborate with Community Partners to identify hyperlocal opportunities for integrated HIV, harm
reduction, and addiction services. Specifically, we will use qualitative methods to identify barriers and
opportunities for integrated care from the perspective of service organizations and PWID.
Public Health Relevance Statement
NARRATIVE
The proposed research activities will contribute a fundamental, hyperlocal knowledge of HIVrisk among personswhoinjectdrugs in Alabama. This data is essential to identify and prioritize communities for HIV prevention
services, in addition to harm reduction and addiction interventions. We will not reach the ambitious aims of the
Ending the HIV Epidemic Initiative without tailoring prevention efforts to meet the needs of PWID, a group who
is most marginalized and at heightened risk of HIV.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AIDS preventionAcquired Immunodeficiency SyndromeAddressAlabamaBacterial InfectionsBehaviorCOVID-19CaringCollaborationsCommunicable DiseasesCommunitiesCountyDataDisease OutbreaksDrug usageEpidemicEpidemiologicMethodsEpidemiologic MonitoringEpidemiologyEventEvidence based practiceFentanylGeographic DistributionGoalsHIVHIV diagnosisHIV disparitiesHIVriskHIV/HCVHarm ReductionHealthHealth Service AreaHepatitis C virusHospitalizationHospitalsInfectionInfrastructureInjecting drug userInjectionsInterventionKnowledgeLegalLifeMapsMedicaidMedicalMethamphetamineNaloxoneNatureOutcomeOverdosePharmaceutical PreparationsPopulationPositioning AttributePovertyPreventionProviderPublic HealthQualitative MethodsQualitative ResearchReportingResearchResearch ActivityResourcesRiskRuralScientistServicesSiteSurrogate MarkersTimeTransactTranslatingViral Load resultVirus DiseasesWorkacute careaddictioncare systemscommunity based participatory researchcommunity buildingcommunity engagementfentanyl testhigh riskimplementation strategyintegrated caremarginalizationnovelopioid overdoseopioid use disorderpandemic diseaseperson centeredpre-exposure prophylaxisprevention serviceprimary care providerpublic health emergencyreturn to userural countiesruralityscale upservice organizationsexsubstance usesurveillance datatest striptreatment center
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
063690705
UEI
YND4PLMC9AN7
Project Start Date
01-March-1997
Project End Date
31-May-2024
Budget Start Date
12-September-2023
Budget End Date
31-May-2024
Project Funding Information for 2023
Total Funding
$222,750
Direct Costs
$150,000
Indirect Costs
$72,750
Year
Funding IC
FY Total Cost by IC
2023
National Institute of Allergy and Infectious Diseases
$222,750
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 3P30AI027767-35S5
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3P30AI027767-35S5
Patents
No Patents information available for 3P30AI027767-35S5
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3P30AI027767-35S5
Clinical Studies
No Clinical Studies information available for 3P30AI027767-35S5
News and More
Related News Releases
No news release information available for 3P30AI027767-35S5
History
No Historical information available for 3P30AI027767-35S5
Similar Projects
No Similar Projects information available for 3P30AI027767-35S5